Interleukin-1 is a Biological Marker in Heart Failure-Reference-Cited by-同舟云学术

Interleukin-1 is a Biological Marker in Heart Failure

Published:2022-11-29 Issue:6 Volume:12 Page:422-429
ISSN:2411-6564
Container-title:The Russian Archives of Internal Medicine
language:
Short-container-title:Arhivʺ vnutrennej mediciny

Author:

Alieva A. M.¹^ORCID,Kislyakov V. A.¹,Voronkova K. V.¹,Reznik E. V.¹^ORCID,Arakelyan R. A.¹^ORCID,Saryev M. N.²^ORCID,Valiev R. K.²^ORCID,Rakhaev A. M.³,Hasanova E. T.¹,Kalova M. R.¹^ORCID,Nikitin I. G.¹^ORCID

Affiliation:

1. Federal State Autonomous Educational Institution of Higher Education «Russian National Research Medical University named after N.I. Pirogov» of the Ministry of Health of Russia

2. State budgetary institution of health care of the city of Moscow «Moscow Clinical Research Center named after A.S. Loginov» of the Moscow Department of Health

3. Federal State Institution «Main Bureau of Medical and Social Expertise in the Kabardino-Balkarian Republic» of the Ministry of Labor and Social Protection of the Russian Federation

Abstract

Inflammation is a universal response of a living organism to various damaging factors and is aimed at restoring tissue integrity and minimizing cell death. Proinflammatory cytokines, in particular interleukins, are active participants in the inflammatory response. In patients with heart failure, inflammatory reactions lead to damage to cardiomyocytes, their apoptosis and activation of neurohumoral systems, which contribute to the initiation of myocardial hibernation and mechanisms of its remodeling. The purpose of this review is to consider IL-1 as a diagnostic and prognostic marker in heart failure, as well as the effect of treatment with a recombinant form of IL-1R on the course of the disease.

Publisher

Synapse, LLC

Subject

General Medicine

Reference42 articles.

1. Tsao C.W., Lyass A., Enserro D. et al. Temporal trends in the incidence of and mortality associated with heart failure with preserved and reduced ejection fraction. JACC: heart failure. 2018; 6(8): 678-685. DOI: 10.1016/j. jchf.2018.03.006.

2. Fomin I.V. Chronic heart failure in the Russian Federation: what we know today and what we must do. Russian journal of cardiology. 2016; (8):7-13. DOI: 10.15829/1560-4071-2016-8-7-13 [in Russian].

3. Maggioni A.P., Dahlström U., Filippatos G. et al. EURObservational Research Programme: regional differences and 1-year followup results of the Heart Failure Pilot Survey (ESC-HF Pilot). European journal of heart failure. 2013;15(7) :808-817. DOI: 10.1093/eurjhf/hft050.

4. Alieva A.M., Reznik E.V., Hasanova E.T. et al. Clinical significance of the determination of blood biomarkers in patients with chronic heart failure. Archive of Internal Medicine. 2018; 8(5):333-345. DOI: 10.20514 / 2226-6704-2018-8-5-333-345 [in Russian].

5. Gasparyan A.Zh., Shlevkov N.B., Skvortsov A.A. Possibilities of modern biomarkers for assessing the risk of developing ventricular tachyarrhythmias and sudden cardiac death in patients with chronic heart failure. Kardiologiia. 2020;60(4):101–108. DOI:10.18087/cardio.2020.4. n487 [in Russian].

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Interleukin-38 and cardiovascular pathology: literature review;CardioSomatics;2023-12-20